The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
Clinical trial NCT05928455 · UNKNOWN
Trial details
- NCT number
- NCT05928455
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-14
- Primary completion
- 2022-10-10
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.